Recent advances in tendinopathy

Challoumas, Dimitrios; Biddle, Mairiosa; Millar, Neal L.

doi:10.12703/b/9-16

Cited by 15 publications

(11 citation statements)

References 67 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Это сопровождается снижением прочности сухожилия и энтезиса, повышением механического стресса и более легкой индукцией локального воспаления. Кроме того, неоангиогенез и спраутинг (разрастание новообразованных нервных волокон) (5):88-93 определяют повышение периферической болевой чувствительности и способствуют развитию периферической гипералгезии [10][11][12][13].…”

Section: патогенез помтunclassified

Hyaluronic acid in rheumatic disorders of the periarticular soft tissues: a brief descriptive review

Karateev¹

2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Periarticular soft tissue disorders (PSTD) are typical manifestation of immunoinflammatory rheumatic diseases, primarily spondyloarthritis. However, in real clinical practice, physicians involved in the management of patients with musculoskeletal diseases often have to deal with "non-systemic" PSTD resulting from trauma, physical exertion, or degenerative processes associated with endocrine, metabolic, and cardiovascular diseases. PSTD causes acute and chronic pain, significant impairment of function and deterioration in the quality of life. The treatment of this pathology is complex and includes non-drug methods, painkillers and local injection therapy. Hyaluronic acid (HA) drugs occupy an important place in this treatment. Their use is pathogenetically justified, because when the tendon and enthesis are involved, the internal environment (intercellular matrix) change, and its basis is natural hyaluronate, which provides the viscoelastic properties of biological structures, as well as regulates metabolism, proliferative and immune processes. A relatively low molecular weight HA drug (530–730 kDa) has favorable rheological parameters, anti-inflammatory and anabolic potential, which makes it the drug of choice for local injection therapy of PSTD. This review briefly presents data on the pathogenesis of PSTD and the advisability of HA drugs use for its therapy, as well as the evidence base for the use of HA (530–730 kDa) in various types of ligamentous apparatus lesions.

show abstract

Section: патогенез помтunclassified

Hyaluronic acid in rheumatic disorders of the periarticular soft tissues: a brief descriptive review

Karateev¹

2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

“…Tendinopathy is histologically characterized by a failed healing response of hypercellularity, hypervascularity and rounding of tenocytes with loss of parallel cell arrangement [ [33] , [34] , [35] ]. The collagen type III/type I ratio and sulfated glycosaminoglycan production increase in tendinopathy.…”

Section: Common Inflammatory Mediators Linking Obesity and Tendinopathymentioning

confidence: 99%

“…Tendinopathy is previously considered as a degenerative disease with an absence of infiltration of inflammatory cells [ [36] , [37] , [38] ]. However, recent studies have reported signs of inflammation, including the presence of inflammatory cells or an increase in inflammatory markers in the pathological clinical samples [ 33 , 34 , [39] , [40] , [41] ]. The discrepancy is likely due to the sub-optimal method used for the detection of inflammatory cells in the earlier studies.…”

Section: Common Inflammatory Mediators Linking Obesity and Tendinopathymentioning

confidence: 99%

Inflammatory mechanisms linking obesity and tendinopathy

Lui

Yung

2021

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

Chronic tendinopathy is a debilitating tendon disorder with disappointing treatment outcomes. This review focuses on the potential roles of chronic low-grade inflammation in promoting tendinopathy in obesity. A systematic literature search was performed to identify all clinical studies supporting the actions of obesity-associated inflammatory mediators in the development of tendinopathy. The mechanisms of obesity-induced chronic inflammation in adipose tissue are firstly reviewed. Common inflammatory mediators potentially linking obesity and the development of tendinopathy, and their association with mechanical overuse, are discussed, along with pre-clinical evidences and a systematic literature search on clinical studies. The potential contribution of local adipose tissues in the promotion of inflammation, pain and tendon degeneration is then discussed. The future research directions are proposed. Translational potential statement Better understanding of the roles of obesity-associated inflammatory mediators on tendons will clarify the pathophysiological drivers of tendinopathy in patients with obesity and identify possible treatment targets. Further studies on the mechanisms of obesity-induced chronic inflammation on tendon are a promising direction for the treatment of tendinopathy.

show abstract

“…Tendinopathy is multifactorial pathology, that could lead to chronic pain and functional impairment [ 1 ]. The rotator cuff [ 2 ], the long head of the biceps [ 3 ], the wrist extensors and flexors [ 4 ], the adductors [ 5 ], the patellar tendon, the Achilles tendon [ 6 ] and the posterior tibial tendon [ 7 ] are the most affected tendons.…”

Section: Introductionmentioning

confidence: 99%

“…There are currently no treatments of choice for tendinopathies as no strong evidence has yet been found that one treatment is better than another [ 1 , 23 , 24 ]. Until a few years ago, eccentric exercise [ 25 , 26 , 27 ] and extracorporeal shock wave therapy (ESWT) [ 28 ] showed significant effects on both pain and functional recovery.…”

Section: Introductionmentioning

confidence: 99%

Low Molecular Weight Hyaluronic Acid (500–730 Kda) Injections in Tendinopathies—A Narrative Review

Frizziero

Vittadini²,

Bigliardi

et al. 2021

JFMK

View full text Add to dashboard Cite

Tendinopathies are common causes of pain and disability in general population and athletes. Conservative treatment is largely preferred, and eccentric exercise or other modalities of therapeutic exercises are recommended. However, this approach requests several weeks of consecutive treatment and could be discouraging. In the last years, injections of different formulations were evaluated to accelerate functional recovery in combination with usual therapy. Hyaluronic acid (HA) preparations were proposed, in particular LMW-HA (500–730 kDa) for its unique molecular characteristics in favored extracellular matrix homeostasis and tenocyte viability. The purpose of our review is to evaluate the state-of-the-art about the role of 500–730 kDa in tendinopathies considering both preclinical and clinical findings and encourage further research on this emerging topic.

show abstract

Recent advances in tendinopathy

Cited by 15 publications

References 67 publications

Hyaluronic acid in rheumatic disorders of the periarticular soft tissues: a brief descriptive review

Hyaluronic acid in rheumatic disorders of the periarticular soft tissues: a brief descriptive review

Inflammatory mechanisms linking obesity and tendinopathy

Low Molecular Weight Hyaluronic Acid (500–730 Kda) Injections in Tendinopathies—A Narrative Review

Contact Info

Product

Resources

About